Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.30 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.30 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20040162 | 0.96 | MAPT (0.34) | MAPTMEN1KMT2AKDM4EPABPC1 | |
| SCHEMBL20040195 | 0.95 | MEN1 (0.32) | MAPTMEN1KMT2AKDM4EPABPC1 | |
| SCHEMBL20040165 | 0.92 | MEN1 (0.32) | MAPTMEN1KMT2AKDM4EPABPC1 | |
| SCHEMBL20040166 | 0.91 | MEN1 (0.32) | MAPTMEN1KMT2AKDM4EPABPC1 | |
| SCHEMBL20042503 | 0.91 | MEN1 (0.32) | MAPTMEN1KMT2AKDM4EPABPC1 | |
| SCHEMBL20042502 | 0.89 | KDM4E (0.31) | MAPTMEN1KMT2AKDM4EPABPC1 | |
| SCHEMBL20040211 | 0.88 | — | — | |
| SCHEMBL20040180 | 0.88 | — | — | |
| SCHEMBL20042501 | 0.87 | MEN1 (0.32) | MAPTMEN1KMT2AKDM4EPABPC1 | |
| SCHEMBL20040197 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3306690-B1 | ORGANIC SEMICONDUCTING COMPOUNDS | RAYNERGY TEK INC (TW) | 2022-09-07 | — | — | EP | disclosed |
| US-10411190-B2 | Organic semiconducting compounds | MERCK PATENT GMBH (DE) | 2019-09-10 | — | — | US | disclosed |
| EP-3306690-A1 | ORGANIC SEMICONDUCTING COMPOUNDS | Merck Patent GmbH (DE) | 2018-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10411190-B2 | Organic semiconducting compounds | OCIAD2, OCIAD1, OSTC | MAPT 45/4885MEN1 2981/4885KMT2A 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.